
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Supplements and Featured Publications
almost 31 years ago
Introductionalmost 31 years ago
Switch Therapy: Development, Implementation, and Economicsalmost 31 years ago
CPE Questions





